Biocryst Pharmaceuticals (BCRX) Net Cash Flow (2010 - 2026)

Biocryst Pharmaceuticals has reported Net Cash Flow for 17 years, with the latest figure at $82.1 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 76641.12% year-over-year to $82.1 million; the trailing twelve-month figure through Mar 2026 stood at $65.8 million (up 214.67% YoY), and the FY2025 full-year result was -$16.3 million, down 213.34% from the prior year.
• Net Cash Flow for Q1 2026 stood at $82.1 million, up from -$9.5 million in the prior quarter.
• The five-year high for Net Cash Flow was $82.1 million in Q1 2026, with the low at -$149.5 million in Q1 2023.
• Historically, Net Cash Flow has averaged -$19.7 million across 5 years, with a median of -$5.8 million in 2024.
• Annual changes were most pronounced in 2022 — Net Cash Flow sank 665.62% — and 2026, when it surged 76641.12%.
• Biocryst Pharmaceuticals' Net Cash Flow stood at $57.6 million in 2022, then tumbled by 170.47% to -$40.6 million in 2023, then soared by 121.11% to $8.6 million in 2024, then slumped by 210.8% to -$9.5 million in 2025, then surged by 965.44% to $82.1 million in 2026.
• The last three Net Cash Flow figures came in at $82.1 million (Q1 2026), -$9.5 million (Q4 2025), and -$3.6 million (Q3 2025), per Business Quant data.